BACKGROUND: Left atrial (LA) sphericity (LASP) is a new remodeling parameter based on LA shape analysis, with independent predictive value for recurrence after atrial fibrillation (AF) ablation. OBJECTIVES: To evaluate the association between LASP and thromboembolic events (TE) in patients with AF. METHODS: Twenty-nine AF patients and prior TE and 29 age- and gender-matched controls were included. LASP was calculated using a 3D-LA reconstruction. The LA appendage (LAA) volume and morphology were assessed. ROC curve analysis was performed for LASP, LA volume, LAA volume, and CHAD/CHA2 D-VASc scores (Stroke2 -the grouping variable-was excluded). RESULTS: Mean age of the study population was 61 ± 11 years (79.3% males, 53.4% hypertension, 8.6% diabetes). Patients with prior TE had higher LASP than those without (82.5 ± 3.3% vs. 80.2 ± 3.1%, P = 0.008); there were no differences in CHAD or CHA2 D-VASc scores, LA volume, LAA volume, or LAA morphology. The C-statistic was higher for LASP (0.71) than for other tested variables (CHAD score = 0.58, CHA2 D-VASc score = 0.59, LA volume = 0.50, LAA volume = 0.46; P < 0.01 for all vs. LASP). The best cutoff value for LASP was 83.6% (sensitivity 0.52, specificity 0.90). Logistic regression analysis showed predictive value for LASP (OR 1.26 per each 1% increase [1.85-52.20], P = 0.013), but not for clinical risk scores. The addition of LASP to the CHAD and CHA2 D-VASc scores increased the predictive value over the risk scores alone (P = 0.004), and reclassified 45.5% of patients with CHAD = 0 (no anticoagulation indicated) to moderate-risk (anticoagulation indicated). CONCLUSION: LA sphericity is associated with prior TE in AF patients and improves the performance of the CHAD and CHA2 D-VASc scores alone.
BACKGROUND: Left atrial (LA) sphericity (LASP) is a new remodeling parameter based on LA shape analysis, with independent predictive value for recurrence after atrial fibrillation (AF) ablation. OBJECTIVES: To evaluate the association between LASP and thromboembolic events (TE) in patients with AF. METHODS: Twenty-nine AFpatients and prior TE and 29 age- and gender-matched controls were included. LASP was calculated using a 3D-LA reconstruction. The LA appendage (LAA) volume and morphology were assessed. ROC curve analysis was performed for LASP, LA volume, LAA volume, and CHAD/CHA2 D-VASc scores (Stroke2 -the grouping variable-was excluded). RESULTS: Mean age of the study population was 61 ± 11 years (79.3% males, 53.4% hypertension, 8.6% diabetes). Patients with prior TE had higher LASP than those without (82.5 ± 3.3% vs. 80.2 ± 3.1%, P = 0.008); there were no differences in CHAD or CHA2 D-VASc scores, LA volume, LAA volume, or LAA morphology. The C-statistic was higher for LASP (0.71) than for other tested variables (CHAD score = 0.58, CHA2 D-VASc score = 0.59, LA volume = 0.50, LAA volume = 0.46; P < 0.01 for all vs. LASP). The best cutoff value for LASP was 83.6% (sensitivity 0.52, specificity 0.90). Logistic regression analysis showed predictive value for LASP (OR 1.26 per each 1% increase [1.85-52.20], P = 0.013), but not for clinical risk scores. The addition of LASP to the CHAD and CHA2 D-VASc scores increased the predictive value over the risk scores alone (P = 0.004), and reclassified 45.5% of patients with CHAD = 0 (no anticoagulation indicated) to moderate-risk (anticoagulation indicated). CONCLUSION: LA sphericity is associated with prior TE in AFpatients and improves the performance of the CHAD and CHA2 D-VASc scores alone.
Authors: Michael Ghannam; Hong Jun Yun; Edward P Ficaro; Hamid Ghanbari; John J Lazarus; Matthew Konerman; Ravi V Shah; Richard Weinberg; James R Corbett; Hakan Oral; Venkatesh L Murthy Journal: J Nucl Cardiol Date: 2018-09-06 Impact factor: 5.952
Authors: Sotirios Nedios; Frank Lindemann; Jordi Heijman; Harry J G M Crijns; Andreas Bollmann; Gerhard Hindricks Journal: Herz Date: 2021-07-05 Impact factor: 1.443
Authors: Erik T Bieging; Alan Morris; Lowell Chang; Lilas Dagher; Nassir F Marrouche; Joshua Cates Journal: Int J Cardiovasc Imaging Date: 2021-05-06 Impact factor: 2.316
Authors: Juliane Herm; Johannes Schurig; Martin R Martinek; Reinhard Höltgen; Alexander Schirdewan; Paulus Kirchhof; Marcus Wieczorek; Helmut Pürerfellner; Peter U Heuschmann; Jochen B Fiebach; Karl Georg Haeusler Journal: BMC Cardiovasc Disord Date: 2019-03-12 Impact factor: 2.298
Authors: Sotirios Nedios; Soroosh Sanatkhani; Michael Oladosu; Timm Seewöster; Sergio Richter; Arash Arya; Jordi Heijman; Harry J G M Crijns; Gerhard Hindricks; Andreas Bollmann; Prahlad G Menon Journal: Int J Cardiol Heart Vasc Date: 2021-02-26